Maria Rosa Ballester

Publication Activity (10 Years)

Years Active: 2022-2022
Publications (10 Years): 3

Top Topics

Squamous Cell Carcinoma

Randomized Controlled Trial

Drug Administration

Top Venues

Gates open research

This page only lists publications with an associated author ORCID identifier.

Publications

Alejandro Javier Krolewiecki, Wendemagegn Enbiale, Javier Gandasegui, Lisette Van Lieshout, Stella Kepha, Augusto Messa Junior, Michel Bengtson, Woynshet Gelaye Yalew, Valdemiro Escola, María Martinez-Valladares, María Cambra-Pellejà, Jaime Algorta, Helena Martí-Soler, Pedro Fleitas, Maria Rosa Ballester, Stephen R Doyle, Nana Aba Williams, Almudena Legarda, Inácio Mandomando, Charles Mwandawiro, José Muñoz
An adaptive phase II/III safety and efficacy randomized controlled trial of single day or three-day fixed-dose albendazole-ivermectin co-formulation versus albendazole for the treatment of Trichuris trichiura and other STH infections. ALIVE trial protocol. Gates open research 6 (2022)
Alejandro Javier Krolewiecki, Wendemagegn Enbiale, Javier Gandasegui, Lisette Van Lieshout, Stella Kepha, Augusto Messa Junior, Michel Bengtson, Woynshet Gelaye Yalew, Valdemiro Escola, María Martinez-Valladares, María Cambra-Pellejà, Jaime Algorta, Helena Martí-Soler, Pedro Fleitas, Maria Rosa Ballester, Stephen R Doyle, Nana Aba Williams, Almudena Legarda, Inácio Mandomando, Charles Mwandawiro, José Muñoz
An adaptive phase II/III safety and efficacy randomized controlled trial of single day or three-day fixed-dose albendazole-ivermectin co-formulation versus albendazole for the treatment of Trichuris trichiura and other STH infections. ALIVE trial protocol. Gates open research 6 (2022)
Alejandro Javier Krolewiecki, Wendemagegn Enbiale, Javier Gandasegui, Lisette Van Lieshout, Stella Kepha, Augusto Messa Junior, Michel Bengtson, Woynshet Gelaye Yalew, Valdemiro Escola, María Martinez-Valladares, María Cambra-Pellejà, Jaime Algorta, Helena Martí-Soler, Pedro Fleitas, Maria Rosa Ballester, Stephen R Doyle, Nana Aba Williams, Almudena Legarda, Inácio Mandomando, Charles Mwandawiro, José Muñoz
An adaptive phase II/III safety and efficacy randomized controlled trial of single day or three-day fixed-dose albendazole-ivermectin co-formulation versus albendazole for the treatment of Trichuris trichiura and other STH infections. ALIVE trial protocol. Gates open research 6 (2022)